<DOC>
	<DOCNO>NCT02849782</DOCNO>
	<brief_summary>This prospective monocentric open label trial realize Laboratory Clinical Functional Exploration Movement University Hospital Besancon . Cognitive evaluation : 7 day fampridine treatment initiation ( Pre 1 ) , day fampridine treatment initiation ( Pre 2 ) , 14 21 day fampridine treatment initiation , respectively Post 1 Post 2 . Gait evaluation assess Pre 1 , Pre 2 Post 1 . Fampridine prescribe accord guideline issue French Health Products Safety Agency dose 10 mg twice daily . Fampridine indicate improvement walk MS patient walk disability ( EDSS 4-6.5 ) . A walking test recommend evaluate improvement 2 week treatment . According practitioner evaluation Pre 2 Post 1 ( i.e . fampridine treatment ) , patient classify 2 group : responder whose clinical status improve non-responders whose clinical status improve .</brief_summary>
	<brief_title>Short Long Term Multiple Outcomes Persons With Multiple Sclerosis Treated Fampridine .</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) chronic neurological disorder affect young middle-aged adult female male ratio 3:1 . The cause MS unknown although involves genetic susceptibility environmental exposure . Since know cure MS , main goal treatment delay progression disease improve health-related quality life ( HRQoL ) mask patient ' symptom . Among several symptom MS ( e.g. , motor cognitive impairment , optic neuritis , fatigue , pain , urinary dysfunction ) , gait impairment , define activity limitation International Classification Functioning Disability Health , one common disable dysfunction Persons Multiple Sclerosis PwMS . Studies report approximately 75 % individual MS experience clinically significant walking disturbance . Likewise , fatigue , impairment information-processing speed ( IPS ) , attention , work memory executive function occur MS worsen evolution disease . Studies show MS symptomatic treatment fampridine ( 4-aminopyridine ) associate improvement walk muscle strength possibly cognition , vision , fatigue spasticity . Indeed , fampridine potassium channel blocker reduce leakage ionic current channel , prolong repolarization thus , enhance action-potential formation demyelinate axon . Presumably , enhance action-potential formation , impulse might conduct central nervous system ( CNS ) neurological function could ameliorate . In recent phase III study , Goodman et al . investigated fampridine effect walk individual MS time 25-foot walk test ( T25FW ) . Improvement walk velocity ( â‰ˆ25 % baseline ) find 35-43 % individual interventional group . However , improvement neuronal conduction induce fampridine might limit short distance gait even motor function might also improve long distance ambulation cognitive function . Different assessment use measure gait impairment multiple sclerosis , include Timed 25-Foot Walk ( T25FW ) , Six-Minute Walk Test ( 6MWT ) , spatio-temporal gait parameter measure instrumented walkway Timed Up Go test ( TUG ) . These different assessment perform different condition : simple task , fast speed dual task . In last case , gait associate cognitive another motor task . For cognitive assessment , Symbol Digit Modalities Test ( SDMT ) verbal fluency use previous study . The aim study evaluate impact fampridine gait evaluate long distance test evaluate impact fampridine fatigue cognition . Assessments patient perform 7 day fampridine treatment initiation ( Pre 1 ) , day fampridine treatment initiation ( Pre 2 ) , 14 21 day fampridine treatment initiation , respectively Post 1 Post 2 . Gait evaluation assess Pre 1 , Pre 2 Post 1 . The first two assessment intend evaluate variability measurement without treatment . A measurement activity perform accelerometer period cover first two assessment . The third assessment intend measure clinical improvement . The fourth seek show potentially delay action fampridine cognition .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>MS diagnostic regard modify McDonald criterion EDSS status 4.0 6.5 patient able walk 6 minute increase MS symptom previous 60 day history epilepsy epileptic seizure immunotherapy change previous 60 day begin antispastic treatment previous 30 day begin treatment able decrease fatigue symptom previous 30 day modification rehabilitation program study renal insufficiency ( creatinine clearance &lt; 80ml.min1 give CockroftGault formula ) concomitant treatment organic cation transporter 2 inhibitor hypersensitivity fampridine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Gait analysis</keyword>
	<keyword>Fampridine</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Daily activity</keyword>
	<keyword>Cognition</keyword>
</DOC>